External Quality Assurance (EQA) Program for

Neonatal G6PD Screening Test



2018 External Quality Assurance (EQA) Program for Neonatal G6PD Screening Test [EQA Survey Schedule for 2018]

Application Forms

G6PD EQA MIS System [login]

FAQ : [website security certificate Problem]

[Chinese Version]


@@Glucose-6-phosphate dehydrogenase (G6PD; EC1.1.1.49) deficiency is the most common enzymopathic disease in Southeast Asia and other tropical areas worldwide. This X-linked genetic disorder (MIM 305900) has been found to be an important cause of neonatal jaundice and acute haemolytic anemia in the southern Chinese population in Taiwan.  In order to reduce the complications of G6PD deficiency, such as kernicterus, permanent neurological damage and death, nationwide neonatal screening for G6PD deficiency was started on 1 July 1987 after a pilot project conducted between November 1984 and June 1987 had demonstrated the practicality and the efficiency of neonatal screening of G6PD deficiency in Taiwan.  The effective collection rate has reached more than 99% of all newborns in Taiwan since 1996 and the overall incidence rate of G6PD deficiency was found to be about 2%.  To assess the reliability and to improve the quality of the screening tests performed by each neonatal screening center, an external quality assurance (EQA) program for determination for blood G6PD activity was developed since 1999.

        Periodically, 10 QC specimens were randomly picked for each survey and distributed to each neonatal screening laboratory by speed post delivery.  Reports were requested to be returned by facsimile (and internet submission since 2005) within 4 days for screening centers in Taiwan and 8 days for overseas screening centers.  For each QA survey, the G6PD activity of the QC dried blood spots was determined by quantitative assay13 to set the reference values before the QC specimens were send out.  The results reported by the screening centers were evaluated against the consensus result and compared with the quantitative reference values determined by our laboratory.  The summary report for each survey was published on website within two weeks after the survey started.  

Participating Laboratories

  • Australia
  • [SA Neonatal Screening Laboratory, North Adelaide]
  • Austria
  • [ARCHIMED Life Science GmbH ]
  • China (Mainland)
  • [Foshan Neonatal Screening Center] [Fujian Neonatal Screening Center, Fuzhou] [Guangzhou Neonatal Center] [Hunan Neonatal Screening Center][Meizhou Woman and Child Hospital Newborn Screening Center, Meizhou] [Nanning Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning] [Maternal and Children Health Hospital of LiuZhou, Guangxi] [Qingdao Women and Children's Hospital] [Shanghai Children's Hospital] [Shanghai Neonatal Screening Center-Shanghai] [Shenzhen Neonatal Screening Center] [Xiamen's Maternal & Child Health Care Hospital] [Yang Jiang City of Guang Dong Maternal and Children's Hospital, Yangjiang] [Zhanjiang Neonatal Screening Center] [Zhongshan Neonatal Screening Center]

  • Finland
  • [Labsystems Diagnostics Ltd. Vantaa] [PerkinElmer Wallac Inc, Turku]
  • Germany
  • [Bio-Rad Laboratories GmbH] [Screening-Labor Hannover][Synlab Weiden, Weiden]
  • Greece
  • ["Aghia Sophia" Children's Hospital, Athens] [BIOIATRIKI S.A., Athens] [N.DIMOPOULOS SA- RD Diagnostics]
  • India
  • [Dr Lal PathLabs, New Delhi] [Navigene Genetic Science Pvt. Ltd.]  [Sir Ganga Ram Hospital, New Delhi] [PerkinElmer Health Sciences Pvt. Ltd, Tamil Nadu] [PreventiNe Life Care, Navi Mumbai]
  • Lebanon
  • [Faculty of Medicne-USJ, Beirut]
  • Mexico
  • [Ensayos y Tamizajes de Mexico, S.A. de C.V.] [Instituto Nacional de Perinatologia, Del. Miguel Hidalgo] [Genelab SA de CV] [Hospital General De Mexico Dr. Eduardo Liceaga] [Tamizaje Plus S.A. de C.V.]
  • Philippines
  • [National Institutes of Health, Manila] [Newborn Screening Center-Central Luzon] [Newborn Screening Center-Mindanao] [Newborn Screening Center-Northern Luzon] [Newborn Screening Center-Southern Luzon] [Newborn Screening Center-Visayas]
  • Switzerland
  • [Newbornscreening Switzerland]
  • Taiwan
  • [CFOH, Taipei] [NTU Hospital, Taipei] [TIP, Taipei]
  • Thailand
  • [Lerdsin General Hospital] [Queen Sirikit National Institute of Child Health, Bangkok]
  • Turkey
  • [Tanyalcin Tip Laboratory, Izmir]
  • United States
  • [Astoria-Pacific, Inc.]
  • Vietnam
  • [Bionet Vietnam Newborn Screening Lab, Hanoi city] [Centre of Neonatal and Prenatal Screening and Diagnosis (NHOG), Hanoi city] [Hanoi Hospital of Obstetrics and Gynecology - Prenatal Diagnosis and Newborn Screening Center] [Hue University of Medicine and Pharmacy] [Isolabo Medical Laboratoryl, Ho Chi Minh City] [Tu Du Hospital, Ho Chi Minh City]

    Summary Report of EQA Survey for Neonatal G6PD Screening Test :

    January 2018~

    @@@@  1. Survey No : NS2018-01

    @@@@  2. Survey No : NS2018-02

    @@@@  3. Survey No : NS2018-03

    @@@@  4. Survey No : NS2018-04


    July 1998~December 2017

    Publication Related to this G6PD EQA Program

    Preventive Medicine Foundation
    Address : P.O. Box 624 Taipei Xinwei, Taiwan, 10699
    TEL : +886-2-2703-6080 ; Fax : +886-2-2703-6070
    E-mail :

    updated : 31 Oct, 2018